{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T01:32:31Z","timestamp":1793669551026,"version":"4.5.1"},"reference-count":122,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.neurol.2021.07.006","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T07:43:48Z","timestamp":1627631028000},"page":"734-752","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"title":["Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 2: Pharmacological treatment"],"prefix":"10.1016","volume":"177","author":[{"given":"A.","family":"Ducros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"de Gaalon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9076-763X","authenticated-orcid":false,"given":"C.","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Donnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Giraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Gu\u00e9gan-Massardier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6717-9234","authenticated-orcid":false,"given":"M.","family":"Lant\u00e9ri-Minet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Mawet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Moisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Valade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Demarquay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2021.07.006_bib0620","article-title":"Revised guidelines of the French Headache Society for the diagnosis and management of migraine in adults. Part 1: diagnosis and assessment","author":"Demarquay","year":"2021","journal-title":"Rev Neurol"},{"key":"10.1016\/j.neurol.2021.07.006_bib0625","article-title":"Revised guidelines of the French Headache Society for the diagnosis and management of migraine in adults. Part 3: non-pharmacological treatment","author":"Demarquay","year":"2021","journal-title":"Rev Neurol"},{"key":"10.1016\/j.neurol.2021.07.006_bib0630","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1001\/archinte.160.22.3486","article-title":"Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study","volume":"160","author":"Lipton","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.neurol.2021.07.006_bib0635","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/j.1526-4610.2010.01638.x","article-title":"A randomized, placebo-controlled trial of acetaminophen for treatment of migraine headache","volume":"50","author":"Prior","year":"2010","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0640","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s10194-012-0484-z","article-title":"Comparison of tolerability and efficacy of a combination of paracetamol + caffeine and sumatriptan in the treatment of migraine attack: a randomized, double-blind, double-dummy, crossover study","volume":"13","author":"Pini","year":"2012","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2021.07.006_bib0645","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1526-4610.2005.05177.x","article-title":"Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial","volume":"45","author":"Goldstein","year":"2005","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0650","first-page":"CD008040","article-title":"Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults","author":"Derry","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2021.07.006_bib0655","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1212\/WNL.58.11.1660","article-title":"Efficacy of oral ketoprofen in acute migraine: a double-blind randomized clinical trial","volume":"58","author":"Dib","year":"2002","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.07.006_bib0660","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/j.1526-4610.2010.01635.x","article-title":"Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine","volume":"50","author":"Suthisisang","year":"2010","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0665","first-page":"CD008783","article-title":"Diclofenac with or without an antiemetic for acute migraine headaches in adults","author":"Derry","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2021.07.006_bib0670","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1345\/aph.1K121","article-title":"Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis","volume":"41","author":"Suthisisang","year":"2007","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.neurol.2021.07.006_bib0675","doi-asserted-by":"crossref","first-page":"56","DOI":"10.5694\/j.1326-5377.1968.tb27465.x","article-title":"Indomethacin in migraine","volume":"1","author":"Anthony","year":"1968","journal-title":"Med J Aust"},{"key":"10.1016\/j.neurol.2021.07.006_bib0680","first-page":"CD008041","article-title":"Aspirin with or without an antiemetic for acute migraine headaches in adults","author":"Kirthi","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2021.07.006_bib0685","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S1474-4422(19)30146-2","article-title":"Pathophysiology, prevention, and treatment of medication overuse headache","volume":"18","author":"Diener","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2021.07.006_bib0690","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1080\/14737175.2020.1770084","article-title":"Medication overuse headache: an overview of clinical aspects, mechanisms, and treatments","volume":"20","author":"Krymchantowski","year":"2020","journal-title":"Expert Rev Neurother"},{"issue":"8","key":"10.1016\/j.neurol.2021.07.006_bib0695","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.3390\/nu12082259","article-title":"The ambiguous role of caffeine in migraine headache: from trigger to treatment","volume":"12","author":"Nowaczewska","year":"2020","journal-title":"Nutrients"},{"issue":"Suppl. 4","key":"10.1016\/j.neurol.2021.07.006_bib0700","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/head.12601","article-title":"Triptans in the acute treatment of migraine: a systematic review and network meta-analysis","volume":"55","author":"Cameron","year":"2015","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0705","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/0333102413508661","article-title":"Comparative efficacy of triptans for the abortive treatment of migraine: a multiple treatment comparison meta-analysis","volume":"34","author":"Thorlund","year":"2014","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0710","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/S0140-6736(01)06711-3","article-title":"Oral triptans (serotonin 5-HT(1B\/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials","volume":"358","author":"Ferrari","year":"2001","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2021.07.006_bib0715","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.neurol.2012.07.022","article-title":"[Guidelines for the diagnosis and management of migraine in adults and children]","volume":"169","author":"Lanteri-Minet","year":"2013","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2021.07.006_bib0720","first-page":"CD009108","article-title":"Sumatriptan (all routes of administration) for acute migraine attacks in adults\u00a0\u2013\u00a0overview of Cochrane reviews","author":"Derry","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2021.07.006_bib0725","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1007\/s12325-020-01494-9","article-title":"Evaluation of patients with insufficient efficacy and\/or tolerability to triptans for the acute treatment of migraine: a systematic literature review","volume":"37","author":"Leroux","year":"2020","journal-title":"Adv Ther"},{"key":"10.1016\/j.neurol.2021.07.006_bib0730","first-page":"CD008541","article-title":"Sumatriptan plus naproxen for the treatment of acute migraine attacks in adults","volume":"4","author":"Law","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2021.07.006_bib0735","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1177\/0333102413480756","article-title":"Triptan nonresponders: do they exist and who are they?","volume":"33","author":"Viana","year":"2013","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0740","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1046\/j.1468-2982.2002.00404.x","article-title":"Triptans (serotonin, 5-HT1B\/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials","volume":"22","author":"Ferrari","year":"2002","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0745","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1111\/head.12154","article-title":"Examination of unmet treatment needs among persons with episodic migraine: results of the American Migraine Prevalence and Prevention (AMPP) Study","volume":"53","author":"Lipton","year":"2013","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0750","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1212\/WNL.0000000000011216","article-title":"Sex differences in response to triptans: a systematic review and meta-analysis","volume":"96","author":"van Casteren","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.07.006_bib0755","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s10194-019-1046-4","article-title":"Differences in treatment response between migraine with aura and migraine without aura: lessons from clinical practice and RCTs","volume":"20","author":"Hansen","year":"2019","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2021.07.006_bib0760","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s10194-018-0899-2","article-title":"Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache","volume":"20","author":"Steiner","year":"2019","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2021.07.006_bib0765","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.ajem.2014.11.013","article-title":"Critical reappraisal of intravenous metoclopramide in migraine attack: a systematic review and meta-analysis","volume":"33","author":"Eken","year":"2015","journal-title":"Am J Emerg Med"},{"key":"10.1016\/j.neurol.2021.07.006_bib0770","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/head.13527","article-title":"The efficacy and safety of prochlorperazine in patients with acute migraine: a systematic review and meta-analysis","volume":"59","author":"Golikhatir","year":"2019","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0775","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1177\/0333102416653233","article-title":"A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine","volume":"36","author":"Voss","year":"2016","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0780","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1001\/jama.2019.16711","article-title":"Effect of ubrogepant vs. placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II Randomized Clinical Trial","volume":"322","author":"Lipton","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.neurol.2021.07.006_bib0785","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(19)31606-X","article-title":"Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial","volume":"394","author":"Croop","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2021.07.006_bib0790","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/head.13444","article-title":"The emperor's new gepants: are the effects of the new oral CGRP antagonists clinically meaningful?","volume":"59","author":"Tfelt-Hansen","year":"2019","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0795","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s10194-019-1007-y","article-title":"The need for new acutely acting antimigraine drugs: moving safely outside acute medication overuse","volume":"20","author":"van Hoogstraten","year":"2019","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2021.07.006_bib0800","doi-asserted-by":"crossref","first-page":"e2222","DOI":"10.1212\/WNL.0000000000006641","article-title":"Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study","volume":"91","author":"Kuca","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.07.006_bib0805","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1093\/brain\/awz134","article-title":"Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine","volume":"142","author":"Goadsby","year":"2019","journal-title":"Brain J Neurol"},{"key":"10.1016\/j.neurol.2021.07.006_bib0810","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1177\/0333102419889350","article-title":"Lasmiditan for the acute treatment of migraine: subgroup analyses by prior response to triptans","volume":"40","author":"Knievel","year":"2020","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0815","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/jcph.1543","article-title":"Abuse potential of lasmiditan: a phase 1 randomized, placebo- and alprazolam-controlled crossover study","volume":"60","author":"Wilbraham","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.neurol.2021.07.006_bib0820","doi-asserted-by":"crossref","first-page":"e0130733","DOI":"10.1371\/journal.pone.0130733","article-title":"A comparative effectiveness meta-analysis of drugs for the prophylaxis of migraine headache","volume":"10","author":"Jackson","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.neurol.2021.07.006_bib0825","doi-asserted-by":"crossref","first-page":"e0212785","DOI":"10.1371\/journal.pone.0212785","article-title":"Beta-blockers for the prevention of headache in adults, a systematic review and meta-analysis","volume":"14","author":"Jackson","year":"2019","journal-title":"PloS One"},{"key":"10.1016\/j.neurol.2021.07.006_bib0830","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1177\/0333102413515348","article-title":"A comparative study of candesartan versus propranolol for migraine prophylaxis: a randomised, triple-blind, placebo-controlled, double crossover study","volume":"34","author":"Stovner","year":"2014","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0835","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.289.1.65","article-title":"Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial","volume":"289","author":"Tronvik","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.neurol.2021.07.006_bib0840","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/j.1468-2982.2008.01825.x","article-title":"Telmisartan in migraine prophylaxis: a randomized, placebo-controlled trial","volume":"29","author":"Diener","year":"2009","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0845","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/bmj.322.7277.19","article-title":"Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo-controlled, crossover study","volume":"322","author":"Schrader","year":"2001","journal-title":"BMJ"},{"key":"10.1016\/j.neurol.2021.07.006_bib0850","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1097\/j.pain.0000000000001456","article-title":"Flunarizine as prophylaxis for episodic migraine: a systematic review with meta-analysis","volume":"160","author":"Stubberud","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.neurol.2021.07.006_bib0855","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/ane.12626","article-title":"Flunarizine versus topiramate for chronic migraine prophylaxis: a randomized trial","volume":"135","author":"Lai","year":"2017","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.neurol.2021.07.006_bib0860","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.3389\/fphar.2019.01495","article-title":"Flunarizine induced Parkinsonism in migraine group: a nationwide population-based study","volume":"10","author":"Lin","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.neurol.2021.07.006_bib0865","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/nrneurol.2016.93","article-title":"Chronic migraine: risk factors, mechanisms and treatment","volume":"12","author":"May","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2021.07.006_bib0870","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.neurol.2013.09.006","article-title":"[Management of chronic daily headache in migraine patients: medication overuse headache and chronic migraine. French guidelines (French Headache Society, French Private Neurologists Association, French Pain Society)]","volume":"170","author":"Lant\u00e9ri-Minet","year":"2014","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2021.07.006_bib0875","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10194-008-0002-5","article-title":"The effect of sodium valproate on chronic daily headache and its subgroups","volume":"9","author":"Yurekli","year":"2008","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2021.07.006_bib0880","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/1574884712666170329094419","article-title":"Levetiracetam in compare to sodium valproate for prophylaxis in chronic migraine headache: a randomized double-blind clinical trial","volume":"12","author":"Kashipazha","year":"2017","journal-title":"Curr Clin Pharmacol"},{"key":"10.1016\/j.neurol.2021.07.006_bib0885","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jfma.2020.08.020","article-title":"Efficacy of levetiracetam for migraine prophylaxis: a systematic review and meta-analysis","volume":"120","author":"Yen","year":"2020","journal-title":"J Formos Med Assoc Taiwan Yi Zhi"},{"key":"10.1016\/j.neurol.2021.07.006_bib0890","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1111\/head.13615","article-title":"Lamotrigine in the prevention of migraine with aura: a narrative review","volume":"59","author":"Buch","year":"2019","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0895","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/jnnp.36.4.684","article-title":"Amitriptyline in migraine prophylaxis. Changes in pattern of attacks during a controlled clinical trial","volume":"36","author":"Gomersall","year":"1973","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.neurol.2021.07.006_bib0900","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1212\/WNL.26.2.121","article-title":"Amitriptyline in the prophylaxis of migraine. Effectiveness and relationship of antimigraine and antidepressant effects","volume":"26","author":"Couch","year":"1976","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.07.006_bib0905","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1001\/archneur.1979.00500470065013","article-title":"Amitriptyline in migraine prophylaxis","volume":"36","author":"Couch","year":"1979","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2021.07.006_bib0910","doi-asserted-by":"crossref","first-page":"c5222","DOI":"10.1136\/bmj.c5222","article-title":"Tricyclic antidepressants and headaches: systematic review and meta-analysis","volume":"341","author":"Jackson","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.neurol.2021.07.006_bib0915","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1001\/archneur.1987.00520170016015","article-title":"Migraine prophylaxis. A comparison of propranolol and amitriptyline","volume":"44","author":"Ziegler","year":"1987","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2021.07.006_bib0920","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.clinthera.2009.03.020","article-title":"Topiramate versus amitriptyline in migraine prevention: a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group non-inferiority trial in adult migraineurs","volume":"31","author":"Dodick","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.neurol.2021.07.006_bib0925","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.clineuro.2010.02.004","article-title":"Botulinum toxin type A versus amitriptyline for the treatment of chronic daily migraine","volume":"112","author":"Magalh\u00e3es","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.neurol.2021.07.006_bib0930","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1526-4610.1992.hed3202101.x","article-title":"Fluoxetine prophylaxis of migraine","volume":"32","author":"Adly","year":"1992","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0935","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1526-4610.1999.3910716.x","article-title":"Fluoxetine for migraine prophylaxis: a double-blind trial","volume":"39","author":"d\u2019Amato","year":"1999","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0940","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1526-4610.1994.hed3409497.x","article-title":"Double-blind trial of fluoxetine: chronic daily headache and migraine","volume":"34","author":"Saper","year":"1994","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0945","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1468-2982.1998.1805283.x","article-title":"S-fluoxetine in the prophylaxis of migraine: a phase II double-blind randomized placebo-controlled study","volume":"18","author":"Steiner","year":"1998","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0950","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1526-4610.2005.05029.x","article-title":"The efficacy and safety of venlafaxine in the prophylaxis of migraine","volume":"45","author":"Ozyalcin","year":"2005","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0955","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.clineuro.2004.03.004","article-title":"Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study","volume":"107","author":"Bulut","year":"2004","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.neurol.2021.07.006_bib0960","first-page":"CD011681","article-title":"Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults","author":"Banzi","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2021.07.006_bib0965","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1136\/rapm-2019-101207","article-title":"Serotonin-norepinephrine reuptake inhibitors for the prevention of migraine and vestibular migraine: a systematic review and meta-analysis","volume":"45","author":"Wang","year":"2020","journal-title":"Reg Anesth Pain Med"},{"key":"10.1016\/j.neurol.2021.07.006_bib0970","first-page":"1106","article-title":"[Pharmaco-epidemiological study on the prophylactic treatment of migraine. National inquiry on attitude to prescription practices by primary care physicians and neurologists in France]","volume":"156","author":"Lant\u00e9ri-Minet","year":"2000","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2021.07.006_bib0975","first-page":"CD011616","article-title":"Botulinum toxins for the prevention of migraine in adults","volume":"6","author":"Herd","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2021.07.006_bib0980","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1177\/0333102410364676","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial","volume":"30","author":"Aurora","year":"2010","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0985","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1177\/0333102410364677","article-title":"OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial","volume":"30","author":"Diener","year":"2010","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib0990","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s10194-018-0840-8","article-title":"Long-term study of the efficacy and safety of OnabotulinumtoxinA for the prevention of chronic migraine: COMPEL study","volume":"19","author":"Blumenfeld","year":"2018","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2021.07.006_bib0995","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s40264-019-00824-3","article-title":"Long-term safety and tolerability of onabotulinumtoxinA treatment in patients with chronic migraine: results of the COMPEL Study","volume":"42","author":"Winner","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.neurol.2021.07.006_bib1000","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","article-title":"CGRP as the target of new migraine therapies\u00a0\u2013\u00a0successful translation from bench to clinic","volume":"14","author":"Edvinsson","year":"2018","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.neurol.2021.07.006_bib1005","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","article-title":"Targeting calcitonin gene-related peptide: a new era in migraine therapy","volume":"394","author":"Charles","year":"2019","journal-title":"Lancet Lond Engl"},{"issue":"10","key":"10.1016\/j.neurol.2021.07.006_bib1010","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.neurol.2020.04.027","article-title":"Monoclonal antibodies blocking CGRP transmission: an update on their added value in migraine prevention","volume":"176","author":"Schoenen","year":"2020","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2021.07.006_bib1015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12883-020-01633-3","article-title":"Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine\u00a0\u2013\u00a0an updated systematic review and meta-analysis","volume":"20","author":"Deng","year":"2020","journal-title":"BMC Neurol"},{"key":"10.1016\/j.neurol.2021.07.006_bib1020","unstructured":"Clinicaltrials.gov. Head-to-head study of erenumab against topiramate in patients with episodic and chronic migraine (HER-MES). NCT03828539 n.d."},{"key":"10.1016\/j.neurol.2021.07.006_bib1025","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","article-title":"Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study","volume":"392","author":"Reuter","year":"2018","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2021.07.006_bib1030","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.neurol.2021.07.006_bib1035","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/S1474-4422(20)30279-9","article-title":"Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial","volume":"19","author":"Mulleners","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2021.07.006_bib1160","doi-asserted-by":"crossref","first-page":"e013372","DOI":"10.1136\/bmjopen-2016-013372","article-title":"Antidepressant use during pregnancy and the risk of major congenital malformations in a cohort of depressed pregnant women: an updated analysis of the Quebec Pregnancy Cohort","volume":"7","author":"B\u00e9rard","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.neurol.2021.07.006_bib1165","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/OGX.0000000000000738","article-title":"Associations between migraine and adverse pregnancy outcomes: systematic review and meta-analysis","volume":"74","author":"Aukes","year":"2019","journal-title":"Obstet Gynecol Surv"},{"key":"10.1016\/j.neurol.2021.07.006_bib1040","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s10194-019-0979-y","article-title":"CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?","volume":"20","author":"Favoni","year":"2019","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2021.07.006_bib1045","article-title":"Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the WHO pharmacovigilance database","author":"Noseda","year":"2021","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib1050","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1177\/0333102417737779","article-title":"Complete detoxification is the most effective treatment of medication overuse headache: a randomized controlled open-label trial","volume":"38","author":"Carlsen","year":"2018","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib1055","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1212\/WNL.0000000000004371","article-title":"Medication overuse headache: an entrenched idea in need of scrutiny","volume":"89","author":"Scher","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2021.07.006_bib1060","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1111\/ene.14268","article-title":"European Academy of Neurology guideline on the management of medication overuse headache","volume":"27","author":"Diener","year":"2020","journal-title":"Eur J Neurol"},{"issue":"9","key":"10.1016\/j.neurol.2021.07.006_bib1065","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1001\/jamaneurol.2020.1179","article-title":"Comparison of 3 treatment strategies for medication overuse headache: a randomized clinical trial","volume":"77","author":"Carlsen","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2021.07.006_bib1070","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/j.1468-1331.2010.03094.x","article-title":"Reduction in medication overuse headache after short information. The Akershus study of chronic headache","volume":"18","author":"Grande","year":"2011","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.neurol.2021.07.006_bib1075","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1468-2982.2003.00480.x","article-title":"Course of migraine during pregnancy and postpartum: a prospective study","volume":"23","author":"Sances","year":"2003","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib1080","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10194-011-0329-1","article-title":"Headache and migraine during pregnancy and puerperium: the MIGRA-study","volume":"12","author":"Kvisvik","year":"2011","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2021.07.006_bib1085","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.ejogrb.2019.07.021","article-title":"Review of migraine incidence and management in obstetrics and gynaecology","volume":"240","author":"Tanos","year":"2019","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"3","key":"10.1016\/j.neurol.2021.07.006_bib1090","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neurol.2020.05.012","article-title":"Headaches during pregnancy","volume":"177","author":"de Gaalon","year":"2020","journal-title":"Rev Neurol (Paris)"},{"key":"10.1016\/j.neurol.2021.07.006_bib1095","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s10194-017-0816-0","article-title":"Headache and pregnancy: a systematic review","volume":"18","author":"Negro","year":"2017","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2021.07.006_bib1100","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s10654-013-9831-x","article-title":"Triptan safety during pregnancy: a Norwegian population registry study","volume":"28","author":"Nezvalov\u00e1-Henriksen","year":"2013","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.neurol.2021.07.006_bib1105","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/head.12375","article-title":"Final results from the 16-year sumatriptan, naratriptan, and treximet pregnancy registry","volume":"54","author":"Ephross","year":"2014","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib1110","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/head.12500","article-title":"Pregnancy outcome following prenatal exposure to triptan medications: a meta-analysis","volume":"55","author":"Marchenko","year":"2015","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib1115","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1177\/0333102417724152","article-title":"Pregnancy outcome after antimigraine triptan use: a prospective observational cohort study","volume":"38","author":"Spielmann","year":"2018","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib1120","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/ppe.12461","article-title":"Prenatal triptan exposure and neurodevelopmental outcomes in 5-year-old children: follow-up from the Norwegian Mother and Child Cohort Study","volume":"32","author":"Harris G-ME","year":"2018","journal-title":"Paediatr Perinat Epidemiol"},{"key":"10.1016\/j.neurol.2021.07.006_bib1125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/head.14041","article-title":"Management of primary headaches during pregnancy, postpartum, and breastfeeding: a systematic review","volume":"61","author":"Saldanha","year":"2021","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib1130","unstructured":"Centre de r\u00e9f\u00e9rence des agents t\u00e9ratog\u00e8nes; 2020. https:\/\/www.lecrat.fr. n.d."},{"key":"10.1016\/j.neurol.2021.07.006_bib1135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2018.06.002","article-title":"Use of nonsteroidal anti-inflammatory drugs during pregnancy and the risk of miscarriage","volume":"219","author":"Li","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.neurol.2021.07.006_bib1140","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.reprotox.2018.05.003","article-title":"No evidence of adverse pregnancy outcome after exposure to ibuprofen in the first trimester\u00a0\u2013\u00a0Evaluation of the national Embryotox cohort","volume":"79","author":"Dathe","year":"2018","journal-title":"Reprod Toxicol Elmsford N"},{"key":"10.1016\/j.neurol.2021.07.006_bib1145","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s40264-017-0627-x","article-title":"Beta-blocker use in pregnancy and risk of specific congenital anomalies: a European case-malformed control study","volume":"41","author":"Bergman","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.neurol.2021.07.006_bib1150","doi-asserted-by":"crossref","first-page":"665","DOI":"10.7326\/M18-0338","article-title":"\u03b2-blocker use in pregnancy and the risk for congenital malformations: an international cohort study","volume":"169","author":"Bateman","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.neurol.2021.07.006_bib1155","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/bcp.14561","article-title":"Risk of congenital malformations in offspring of women using \u03b2-blockers during early pregnancy: an updated meta-analysis of observational studies","volume":"87","author":"Wu","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.neurol.2021.07.006_bib1170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/0333102417738202","article-title":"The International Classification of Headache Disorders, 3rd edition","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","journal-title":"Cephalalgia Int J Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib1180","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/head.13665","article-title":"Epidemiology and treatment of menstrual migraine and migraine during pregnancy and lactation: a narrative review","volume":"60","author":"Burch","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib1185","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(20)30482-8","article-title":"Menstrual migraine: a distinct disorder needing greater recognition","author":"Vetvik","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2021.07.006_bib1190","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/head.12978","article-title":"Menstrual migraine and treatment options: review","volume":"57","author":"Maasumi","year":"2017","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib1195","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/j.1526-4610.1990.hed3011705.x","article-title":"Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo-controlled study","volume":"30","author":"Sances","year":"1990","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib1200","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.maturitas.2020.07.005","article-title":"Menstrual and perimenopausal migraine: a narrative review","volume":"142","author":"MacGregor","year":"2020","journal-title":"Maturitas"},{"key":"10.1016\/j.neurol.2021.07.006_bib1205","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1129-2377-14-7","article-title":"Triptans in prevention of menstrual migraine: a systematic review with meta-analysis","volume":"14","author":"Hu","year":"2013","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2021.07.006_bib1210","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s10194-018-0896-5","article-title":"Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH)","volume":"19","author":"Sacco","year":"2018","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2021.07.006_bib1215","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s10194-017-0815-1","article-title":"Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC)","volume":"18","author":"Sacco","year":"2017","journal-title":"J Headache Pain"},{"key":"10.1016\/j.neurol.2021.07.006_bib1220","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1111\/head.13796","article-title":"Migraine and ischemic stroke in women. A narrative review","volume":"60","author":"Tietjen","year":"2020","journal-title":"Headache"},{"key":"10.1016\/j.neurol.2021.07.006_bib1225","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14737175.2020.1730816","article-title":"Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research","volume":"20","author":"Ornello","year":"2020","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.neurol.2021.07.006_bib1230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/2053369117731172","article-title":"Migraine, menopause and hormone replacement therapy","volume":"24","author":"MacGregor","year":"2018","journal-title":"Post Reprod Health"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378721006172?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378721006172?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T05:43:49Z","timestamp":1758519829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378721006172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":122,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S0035378721006172"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2021.07.006","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revised guidelines of the French headache society for the diagnosis and management of migraine in adults. Part 2: Pharmacological treatment","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2021.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}